Global Rank
#17519
Country Rank
#494
Market Cap
$314.5 M
Price
$34.32
Change (%)
0.11%
Volume
13,085
Dong-A ST's latest marketcap:
$314.5 M
As of 07/30/2025, Dong-A ST's market capitalization has reached $314.5 M. According to our data, Dong-A ST is the 17519th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
Market Cap | $314.5 M |
Revenue (ttm) | $524.12 M |
Net Income (ttm) | $-565,055.61 |
Shares Out | 9.16 M |
EPS (ttm) | $-0.06 |
Forward PE | 21.05 |
Ex-Dividend Date | 03/13/2025 |
Earnings Date | 07/28/2025 |
Market Cap Chart
Data Updated: 07/30/2025
Dong-A ST's yearly market capitalization.
Dong-A ST has seen its market value drop from ₩705.89 B to ₩434.79 B since 2014, representing a total decrease of 38.41% and an annual compound decline rate (CAGR) of 4.48%.
Date | Market Cap(₩) | Market Cap(USD) | Change (%) | Global Rank |
---|---|---|---|---|
07/30/2025 | ₩434.79 B | $314.5 M | -17.77% | 17519 |
12/30/2024 | ₩528.23 B | $353.91 M | -11.66% | 15297 |
12/28/2023 | ₩597.95 B | $460.42 M | 14.22% | 13582 |
12/29/2022 | ₩523.48 B | $413.55 M | -13.38% | 13484 |
12/30/2021 | ₩604.34 B | $507.65 M | -19.17% | 13259 |
12/30/2020 | ₩747.64 B | $687.83 M | -25.55% | 9873 |
12/30/2019 | ₩1 T | $863.58 M | 13.88% | 7473 |
12/28/2018 | ₩881.81 B | $784.81 M | 4.92% | 7034 |
12/28/2017 | ₩840.46 B | $781.63 M | -5.6% | 8264 |
12/29/2016 | ₩890.36 B | $730.09 M | -24.63% | 7893 |
Company Profile
About Dong-A ST Co., Ltd.
Dong-A ST Co., Ltd. is a pharmaceutical company specializing in the development, manufacturing, and marketing of ethical drugs and medical devices. Founded in 1932 and headquartered in Seoul, South Korea, the company operates both domestically and internationally.
Key Pharmaceutical Products
- Closerin Cap – For active pulmonary and extra-pulmonary tuberculosis.
- Dulastin PFS & Leucostim Injection/PFS – Treats neutropenia in chemotherapy patients.
- Eporon Inj./PFS – Addresses anemia linked to chronic renal failure.
- Gemcit Inj. – Targets non-small cell lung, pancreatic, breast, bladder, and ovarian cancers.
- Gonadopin Inj./PFS – Used for infertility and anovulation treatment.
- Growtropin II Inj./AQ Cartridge – Treats growth failure due to inadequate growth hormone secretion.
- Mainta Inj. – For non-small cell lung cancer and malignant pleural mesothelioma.
- Monotaxel Inj. – Treats breast, lung, prostate, head/neck cancers, and gastric adenocarcinoma.
- Motilitone Tab. – Used in functional dyspepsia treatment.
- Stillen Tab. – Addresses gastritis.
- Suganon Tab. & Sugamet XR Tab. – For type 2 diabetes mellitus.
- Terizidone Tab. – Treats active pulmonary and extra-pulmonary tuberculosis.
- Zydena Tab. – For erectile dysfunction treatment.
Additional Offerings
- Licensed-in and licensed-out pharmaceutical products.
- Medical devices, including high-tech solutions, custom-made products, and artificial cardiac circuits for open-heart surgery.
Frequently Asked Questions
-
What is Dong-A ST's (KRX-170900) current market cap?As of 07/30/2025, Dong-A ST (including the parent company, if applicable) has an estimated market capitalization of $314.5 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Dong-A ST (KRX-170900) rank globally by market cap?Dong-A ST global market capitalization ranking is approximately 17519 as of 07/30/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.